Danaher Corp

Danaher raises €3 bn via senior notes to fund its $2.5 bn Masimo acquisition and boost life‑sciences growth, securing debt at par while preserving cash‑flow and future R&D potential.

Danaher Corp. tops Q1 2026 earnings expectations, boosts 2026 outlook and plans to acquire Masimo, expanding its Life Sciences, bioprocessing, and digital health portfolio.

Danaher Corp’s next quarterly results promise modest EPS growth and slight revenue gains, driven by Life Sciences and Advanced Technologies, with investors eyeing future R&D and market dynamics.

Danaher Corp tops expectations with 8.6% revenue growth, $6.15 EPS, and a bullish outlook on life sciences, diagnostics and tech solutions, boosting investor confidence.

Danaher’s diversified tech & life‑science portfolio thrives on smart integrations and global reach, yet faces rising IP litigation and tightening regulations—learn how the conglomerate turns challenges into growth opportunities.

Danaher’s $5 billion revolving credit facility boosts liquidity, fuels tech R&D and strategic acquisitions, positioning the firm to thrive in value‑based healthcare and outperform industry metrics.

Danaher Corp’s resilient mix of life‑sciences and diagnostics drives modest growth, strong margins, and strategic value‑based pricing—outperforming peers while navigating complex reimbursement models.

Danaher faces a fiduciary‑duty probe while investors trade shares and AI‑manufacturing drives growth—what the outcome means for governance and value.

Danaher’s recent share purchases by Sage Rhino Capital and Joel Isaacson & Co. reveal investors’ confidence in its robust market‑access strategy, patent moat, and M&A pipeline amid looming patent cliffs and evolving competition in diagnostics and ra…

Evercore ISI downgrades Danaher’s target price, sparking debate over the company’s growth prospects and risk profile while its diversified portfolio and innovation pipeline remain key to long‑term value.